8. Huntington disease
197 clinical trials,   171 drugs   (DrugBank: 54 drugs),   82 drug target genes,   144 drug target pathways

Searched query = "Huntington disease", "Huntington chorea"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02231580
(ClinicalTrials.gov)
September 1, 20142/9/2014Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease PatientsA Dose Escalation, Proof of Concept, Phase IIa Study to Investigate the Safety and Tolerability, the Pharmacokinetic and the Pharmacodynamic of BN82451B, Administered Twice Daily Over 4 Weeks, in Male Patients With Huntington's DiseaseHuntington's DiseaseDrug: BN82451B;Drug: PlaceboIpsenNULLTerminated20 Years70 YearsMale17Phase 2Germany
2EUCTR2013-002899-41-DE
(EUCTR)
28/04/201424/01/2014Study to assess the effects of BN82451B and how it is absorbed, distributed and eliminated in the body, when it is given for 4 weeks to men suffering from Hungtington's diseaseA dose escalation, proof of concept, phase IIa study to investigate the safety and tolerability, the pharmacokinetic and thepharmacodynamic of BN82451B, administered twice daily over 4 weeks, in male patients with Huntington’s disease Huntington's disease
MedDRA version: 18.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: BN8251B
INN or Proposed INN: N/A
Other descriptive name: BN82451B
Product Name: BN8251B
INN or Proposed INN: N/A
Other descriptive name: BN82451B
Ipsen PharmaNULLNot RecruitingFemale: no
Male: yes
Phase 2Germany